Publications

2011

  • Wang Y, Kaneko O, Sattabongkot J, Chen JH, Lu F, Chai JY, et al. Genetic polymorphism of Plasmodium vivax msp1p, a paralog of merozoite surface protein 1, from worldwide isolates. Am J Trop Med Hyg. 2011 Feb;84(2):292-7.

  • Tachibana M, Wu Y, Iriko H, Muratova O, MacDonald NJ, Sattabongkot J, et al. N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin Vaccine Immunol. 2011 Aug;18(8):1343-50.

  • Sungkapong T, Culleton R, Yahata K, Tachibana M, Ruengveerayuth R, Udomsangpetch R, et al. Humoral immune responses to Plasmodium vivax subtelomeric transmembrane proteins in Thailand. Southeast Asian J Trop Med Public Health. 2011 Nov;42(6):1313-21.

  • Sirichaisinthop J, Buates S, Watanabe R, Han ET, Suktawonjaroenpon W, Krasaesub S, et al. Evaluation of loop-mediated isothermal amplification (LAMP) for malaria diagnosis in a field setting. Am J Trop Med Hyg. 2011 Oct;85(4):594-6.

  • Roobsoong W, Roytrakul S, Sattabongkot J, Li J, Udomsangpetch R, Cui L. Determination of the Plasmodium vivax schizont stage proteome. J Proteomics. 2011 Aug 24;74(9):1701-10.

  • Miyata T, Harakuni T, Tsuboi T, Sattabongkot J, Ikehara A, Tachibana M, et al. Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development. Infect Immun. 2011 Oct;79(10):4260-75.

  • Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, Tachibana M, et al. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine. Vaccine. 2011 Mar 24;29(15):2720-6.

  • Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science. 2011 Dec 9;334(6061):1372-7.

  • Lumsden JM, Pichyangkul S, Srichairatanakul U, Yongvanitchit K, Limsalakpetch A, Nurmukhambetova S, et al. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion. Infect Immun. 2011 Sep;79(9):3492-500.

  • Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS, et al. Genetic polymorphism in pvmdr1 and pvcrt-o genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-endemic countries. Acta Trop. 2011 Feb;117(2):69-75.

  • Lu F, Gao Q, Chotivanich K, Xia H, Cao J, Udomsangpetch R, et al. In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China. Am J Trop Med Hyg. 2011 Aug;85(2):197-201.

  • Lee WJ, Kim HH, Hwang SM, Park MY, Kim NR, Cho SH, et al. Detection of an antibody against Plasmodium vivax in residents of Gimpo-si, South Korea, using an indirect fluorescent antibody test. Malar J. 2011;10:19.

  • Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J. 2011;10:212.

  • Doi M, Tanabe K, Tachibana S, Hamai M, Tachibana M, Mita T, et al. Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax. Vaccine. 2011 Jun 10;29(26):4308-15.

  • Bonizzoni M, Bourjea J, Chen B, Crain BJ, Cui L, Fiorentino V, et al. Permanent Genetic Resources added to Molecular Ecology Resources Database 1 April 2011-31 May 2011. Mol Ecol Resour. 2011 Sep;11(5):935-6.